Tuberculosis remains one of the deadliest infectious diseases worldwide, particularly in regions with high HIV prevalence and overcrowded healthcare facilities. While treatments exist, the rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB complicates management. Patients who contract resistant strains face prolonged treatment regimens that are less effective and more toxic.In healthcare settings where TB…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
